85) investigated the therapeutic effect of Treg cells on multiple sclerosis by creating antigen-specific Tregs targeting myelin oligodendrocyte glycoprotein (MOG) with CAR and injecting them into experimental autoimmune encephalomyelitis (EAE) models with MS. They found that MOG–CAR–Tregs inhibit the proliferation of effector T cells in vitro. Meanwhile, MOG–CAR–Treg reduced the disease symptoms in EAE mice and reduced the levels of pro-inflammatory cytokines (IL-12, INF-γ) in brain tissue in vivo. The gene discussed is MOG; the disease is multiple sclerosis.